Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6464938 | 0.93 | LMNA (0.54) | LMNASMN1; SMN2HTTGAAMAPK1 | |
| SCHEMBL6248128 | 0.93 | LMNA (0.52) | LMNASMN1; SMN2HTTGAAMAPK1 | |
| SCHEMBL6400205 | 0.91 | LMNA (0.53) | LMNASMN1; SMN2HTTGAAMAPK1 | |
| SCHEMBL6246905 | 0.89 | CCR1 (0.51) | LMNASMN1; SMN2HTTGAAMAPK1 | |
| SCHEMBL6462941 | 0.88 | CCR1 (0.50) | LMNASMN1; SMN2HTTGAAMAPK1 | |
| SCHEMBL6466922 | 0.88 | CCR1 (0.50) | LMNASMN1; SMN2HTTGAAMAPK1 | |
| SCHEMBL6248257 | 0.87 | SMN1; SMN2 (0.48) | LMNASMN1; SMN2HTTGAAMAPK1 | |
| SCHEMBL6465815 | 0.87 | LMNA (0.52) | LMNASMN1; SMN2HTTGAAMAPK1 | |
| SCHEMBL6250625 | 0.86 | SMN1; SMN2 (0.47) | LMNASMN1; SMN2HTTGAAMAPK1 | |
| SCHEMBL6248164 | 0.86 | SMN1; SMN2 (0.47) | LMNASMN1; SMN2HTTGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6974817-B2 | CCR1 receptor antagonists; inhibitors of MIP-1 alpha (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells; macrophage inflammatory protein (MIP) | PFIZER INC. (US) | 2005-12-13 | — | — | US | disclosed |
| US-20050250790-A1 | Novel sulfonic acid derivatives | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| EP-1558258-A1 | USE OF PIPERAZINE SULFONIC ACID DERIVATIVES AS CCR1 ANTAGONISTS FOR THE TREATMENT OF FIBROSIS, ALZHEIMER DISEASE AND OTHER DISORDERS | Pfizer Products Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20050119275-A1 | Salt and crystal forms of (5-chloro-2-{2-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-methanesulfonic acid | PFIZER INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2004113311-A1 | AMORPHOUS UND CRYSTAL FORMS OF (5-CHLORO-2-{2- | PFIZER PRODUCTS INC. (US) | 2004-12-29 | — | — | WO | disclosed |
| EP-1430041-A2 | NOVEL SULFONIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20040116441-A1 | Methods of using sulfonic acid derivatives | PFIZER INC | 2004-06-17 | — | — | US | disclosed |
| WO-2004039377-A1 | USE OF PIPERAZINE SULFONIC ACID DERIVATIVES AS CCR1 ANTAGONISTS FOR THE TREATMENT OF FIBROSIS, ALZHEIMER DISEASE AND OTHER DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| US-20030083335-A1 | Novel sulfonic acid derivatives | HAYWARD MATTHEW M (US) | 2003-05-01 | — | — | US | disclosed |
| WO-2002102787-A2 | NOVEL SULFONIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119275-A1 | Salt and crystal forms of (5-chloro-2-{2-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-methanesulfonic acid | CCR1, CCR6, CCR3 | LMNA 4222/4885SMN1; SMN2 1948/4885HTT 2925/4885 |
| US-20050250790-A1 | Novel sulfonic acid derivatives | MSR1, MYD88, CXCR2 | LMNA 4202/4885SMN1; SMN2 2160/4885HTT 4461/4885 |
| US-20030083335-A1 | Novel sulfonic acid derivatives | CCR1, MSR1, CXCR1 | LMNA 4386/4885SMN1; SMN2 1975/4885HTT 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.